Treatment of chronic hepatitis C virus in the Virginia department of corrections: Can compliance overcome racial differences to response?

American Journal of Gastroenterology

Volumn 99, Issue 5, 2004, Pages 866-872

  Sterling, Richard K ^a   Hofmann, Charlotte M ^b   Luketic, Velimir A ^b   Sanyal, Arun J ^b   Contos, Melissa J ^b   Mills, A Scott ^b   Shiffman, Mitchell L ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; DIRECTLY OBSERVED THERAPY; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PRISON; RACE; RACE DIFFERENCE; SUSTAINED VIROLOGIC RESPONSE; TELECOMMUNICATION; UNITED STATES; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; EPIDEMIOLOGY; ETHNOLOGY; FOLLOW UP; HOSPITALIZATION; ISOLATION AND PURIFICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS; SUBCUTANEOUS DRUG ADMINISTRATION; TELEMEDICINE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AFRICAN AMERICANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PRISONS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TELEMEDICINE; TREATMENT OUTCOME; VIRGINIA;

EID: 2942653306     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.30310.x     Document Type: Article

References (35)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Spaulding A, Greene C, Davidson K, et al. Hepatitis C in state correctional facilities. Prev Med 1999;28:92-100.
3. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1-36.
4. Awofeso N, Harper SE, Levy MH. Prevalence of exposure to hepatitis C virus among prison inmates, 1999. Med J Aust 2000;172:94.
5. Holsen DS, Harthug S, Myrmel H. Prevalence of antibodies to hepatitis C virus and association with intravenous drug abuse and tattooing in a national prison in Norway. Eur J Clin Microbiol Infect Dis 1993;12:673-6.
6. Schwarz TF, Dobler G, Gilch S, et al. Hepatitis C and arboviral antibodies in the island populations of Mauritius and Rodrigues. J Med Virol 1994;44:379-83.
7. Butler TG, Dolan KA, Ferson MJ, et al. Hepatitis B and C in New South Wales prisons: Prevalence and risk factors. Med J Aust 1997;166:127-30.
8. Malliori M, Sypsa V, Psichogiou M, et al. A survey of blood-borne viruses and associated risk behaviours in Greek prisons. Addiction 1998;93:243-51.
9. Anastassopoulou CG, Paraskevis D, Sypsa V, et al. Prevalence patterns and genotypes of GB virus C/hepatitis G virus among imprisoned intravenous drug users. J Med Virol 1998;56:246-52.
10. Vlahov D, Nelson KE, Quinn TC, et al. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol 1993;9:566-9.
11. Ruiz JD, Molitor F, Sun RK, et al. Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system. West J Med 1999;170:156-60.
12. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002;92:1789-94.
13. Kendig N. Hepatitis C management in correctional facilities. Prev Med Manag Care 1 2000;S33-S41.
14. Reindollar RW. Hepatitis C and the correctional population. Am J Med 1999;107:100S-3S.
15. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-63.
16. Seeff LB. Natural history of hepatitis C. Am J Med 1999;107:10S-15S.
17. Tong MJ, el Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332(22):1463-66.
18. Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996;8:324-8.
19. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
20. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112(2):463-72.
21. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000;284:450-6.
22. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000;31:513-20.
23. Levine RA. Treating histologically mild chronic hepatitis C: Monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998;129:323-6.
24. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339(21):1485-92.
25. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
26. Allen SA, Spaulding AC, Osei AM, et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003;138:187-90.
27. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
28. Hammett TM. Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med 2003;138:235-6.
29. De Groot AS, Stubblefield E, Bick J. Hepatitis C: A correctional-public health opportunity. Medscape Infect Dis 2001;1-14. (www.medscape.com/ viewarticle/408298)
30. Shiffman ML, Hofmann CM, Gabbay J, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group. Am J Gastroenterol 2000;95:2928-35.
31. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: Summary of a workshop. Gastroenterology 2000;119(5):1385-96.
32. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999;30:787-93.
33. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119:1317-23.
34. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
35. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.